Intermountain Health has successfully performed the state's first procedure to repair the ascending aorta without major ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six ...

Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of ...

Surgeons in the United States perform nearly 600,000 coronary artery stent procedures and bypass surgeries every year.

Homich said the initial cost estimate for the repair is around $5 million, but bids are still pending. As for improving ...

Advanced glycation end products arise from nonenzymatic reactions between sugars and proteins, contributing to oxidative ...

Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of cardiovascular diseases (CVDs).

Recent research from Georgia State University has shed light on the potential of plant-based diets to prevent and even ...

ViTAA Medical Solutions Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance for AiORTA (TM) Plan, the company's fully automated, hyper-precise aortic ...

Diabetes impacts more than just blood sugar, affecting skin, hair, and immunity. India faces a significant diabetes burden, ...

‘Both GLP-1s and exercise can have significant, but somewhat different, impacts on cardiovascular health. Large trials of GLP ...

Q3 2025 Earnings Call Transcript November 12, 2025 Humacyte, Inc. beats earnings expectations. Reported EPS is $-0.14, ...